Astrazeneca Plc · LSE:AZN
Astrazeneca — ASCO 2026 Investor Event
41 slides from Astrazeneca's conference presentation, Jun 1, 2026
Slide 1: Meet AZN Management: ASCO Investor Event
Meet AZN Management: ASCO Investor Event 1 June 2026
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: AstraZeneca @ ASCO 2026
AstraZeneca @ ASCO 2026 Furthering the AstraZeneca ambition Pascal Soriot, Chief Executive Officer Redefining management of Ghassan Abou-Alfa, Attending Physician embolisation-eligible liver cancer and Professor at Memorial Sloan Kettering Cancer Center Including Q&A session Dave Fredrickson, EVP, O
Slide 4: Furthering the AstraZeneca ambition
Furthering the AstraZeneca ambition Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after" ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 saruparib camizestrant surovatamig Next-g
Slide 6: Phase III pipeline momentum continues across 2026
Phase III pipeline momentum continues across 2026 H1 2026 H2 2026 EMERALD-3 | Imfinzi + Imjudo AVANZAR | Datroway + Imfinzi CROSSING | Tezspire embolisation-eligible hepatocellular carcinoma 1L non-squamous/non-squamous TROP2+ NSCLC eosinophilic esophagitis VOLGA | Imfinzi ± Imjudo NEW1 TROPION-Lung
Slide 7: Strategically investing to deliver growth beyond 2030
Strategically investing to deliver growth beyond 2030 CURRENT PROGRESS NEXT WAVE OF INNOVATION Weight management – laroprovstat PhIII data 2027 – Ongoing trials targeting GLP-1-GCG & amylin and CV risk factors – elecoglipron PhIII initiating – details at ADA – Long-acting agents and new mechanisms A
Slide 8: >80 abstract acceptances at ASCO 2026
>80 abstract 52 poster 25 oral acceptances presentations presentations at ASCO 2026 Transforming care Establishing the pipeline for tomorrow today – Imfinzi/Imjudo | EMERALD-3 (LBA4000), – puxi-sam B7-H4 ADC | BLUESTAR (#4106) US BTD POTOMAC (#4624) – sone-ve Cldn18.2 ADC | CLARITY-PanTumor01 (#4023
Slide 9: EMERALD-3
EMERALD-3 Dr Ghassan Abou-Alfa ATTENDING PHYSICIAN, PROFESSOR OF MEDICINE, MEMORIAL SLOAN KETTERING CANCER CENTER
Slide 10: Rationale for STRIDE in embolisation-eligible HCC
Rationale for STRIDE in embolisation-eligible HCC T-cell priming/activation in lymph node Imjudo (anti-CTLA4) TACE EMERALD-3 Release of tumour antigens Role of STRIDE in Upregulate immune checkpoints VEGF IMMUNITY combination with TACE1 CYCLE and anti-angiogenic Imfinzi therapy Lenvatinib (anti-PD-L
Slide 11: EMERALD-3: Bringing STRIDE to unresectable eeHCC
EMERALD-3: Bringing STRIDE to unresectable eeHCC Study population: Arm A: STRIDE + lenvatinib Primary endpoint: • Pathologically or radiologically + TACE1 (n=293) confirmed HCC • PFS (Arm A vs C; BICR RECIST v1.1) • Not amenable to curative treatment, Key secondary endpoints: but amenable to embolis
Slide 12: EMERALD-3: Statistical considerations
EMERALD-3: Statistical considerations Multiple testing procedure DCO11 PFS (α=0.05)2 (02 Sept 2025) Arm A vs Arm C Is PFS statistically significant? If yes, DCO23 OS (α=0.05)2 (23 Feb 2026) Arm A vs Arm C Is OS statistically significant? If yes, PFS (α=0.05)2 Arm B vs Arm C Is PFS statistically sign
Slide 13: EMERALD-3: Statistically significant and clinically meaningful PFS benefit with STRIDE + lenvatinib + TACE
EMERALD-3: Statistically significant and clinically meaningful PFS benefit with STRIDE + lenvatinib + TACE STRIDE+L+TACE TACE (n=293) (n=292) 100 Total PFS events, n (%) 172 (58.7) 201 (68.8) 90 Median PFS, months (95% CI) 13.0 (12.2–16.7) 9.8 (8.0–11.4) HR (95% CI) 0.70 (0.57–0.86) 80 Stratified lo
Slide 14: EMERALD-3: Strong trend to PFS benefit with STRIDE + TACE
EMERALD-3: Strong trend to PFS benefit with STRIDE + TACE STRIDE+TACE TACE1 100 (n=175) (n=first 175) 90 Total PFS events, n (%) 123 (70.3) 140 (80.0) Median PFS, months (95% CI) 12.9 (10.2–15.9) 8.1 (6.5–10.2) 80 HR (95% CI) 0.71 (0.56–0.91) Proportion of participants alive Nominal p-value (not for
Slide 15: EMERALD-3: Broadly consistent benefit across key subgroups
EMERALD-3: Broadly consistent benefit for STRIDE regimens observed across key subgroups STRIDE+L TACE STRIDE TACE Arm A vs Arm C Arm B vs Arm C HR (95% CI) +TACE (n/N) (n/N) HR (95% CI) +TACE (n/N) (n/N) All subjects 0.70 (0.57–0.86) 172/293 201/292 All subjects 0.71 (0.56–0.91) 123/175 140/175 Geog
Slide 16: EMERALD-3: Exploratory analysis Arm A vs B in non-viral aetiology
EMERALD-3: Pre-planned exploratory analysis shows Arm A vs B PFS improvement in patients with non-viral aetiology STRIDE+L+ STRIDE+TACE STRIDE+L+ STRIDE+TACE Arm A vs Arm B Arm A vs Arm B HR (95% CI) TACE1 (n/N) (n/N) HR (95% CI) TACE1 (n/N) (n/N) All subjects 0.94 (0.73–1.21) 125/175 123/175 ECOG P
Slide 17: EMERALD-3: Trend to OS benefit with STRIDE + lenvatinib + TACE
EMERALD-3: Trend to OS benefit with STRIDE + lenvatinib + TACE STRIDE+L+TACE TACE (n=293) (n=292) Total number of deaths, n (%) 112 (38.2) 124 (42.5) 100 12-mo OS Median OS, months (95% CI) 39.5 (34.1–NC) 34.7 (28.8–NC) 83.2% 18-mo OS HR (95% CI) 0.84 (0.65–1.09) 90 82.0% 77.5% 69.7% Stratified log-
Slide 18: EMERALD-3: Strong favourable trend to OS benefit with STRIDE + TACE
EMERALD-3: Strong favourable trend to OS benefit with STRIDE + TACE STRIDE+TACE TACE1 (n=175) (n=first 175) Total number of deaths, n (%) 69 (39.4) 90 (51.4) 12-mo OS 100 Median OS, months (95% CI) NC (37.7–NC) 32.9 (24.1–43.2) 87.7% 81.5% 18-mo OS HR (95% CI) 0.70 (0.51–0.95) 90 76.4% Nominal p-val
Slide 19: EMERALD-3: Manageable AE profile
EMERALD-3: Manageable AE profile consistent with known safety profiles of STRIDE, lenvatinib and TACE STRIDE + L + TACE STRIDE + TACE TACE (n=287) (n=175) (n=290) Any grade AE, n (%) 286 (99.7) 173 (98.9) 256 (88.3) Possibly related to any study treatment1 280 (97.6) 168 (96.0) 215 (74.1) Provoked b
Slide 20: EMERALD-3: STRIDE-based regimen delivers benefit over TACE
EMERALD-3: STRIDE-based regimen delivers benefit over long-standing standard-of-care TACE ― STRIDE + L + TACE significantly improved PFS vs TACE alone (HR 0.70 (0.57-0.86); p=0.0007) ― STRIDE + L + TACE showed favourable OS trend vs TACE alone (HR 0.84 (0.65-1.09); p=0.1814). OS data maturity 40%, t
Slide 21: Opportunity for Q&A
Opportunity for Q&A Pascal Soriot Susan Galbraith CH IEF E XECUTI VE O FFICE R E VP, ONCOLO GY HAE MATOL OGY R& D KEY EXTERNAL EXPERT Dave Fredrickson Ghassan Abou-Alfa E VP, ONCOLO GY ATT END ING PHYS ICIAN AND HAE MATOL OGY BUSINE SS PROFE SSOR AT ME MORIAL S LOAN KE TT ERING C ANC ER CE NTE R 21
Slide 22: Realising our ambition in Oncology
Realising our ambition in Oncology Dave Fredrickson EVP, ONCOLOGY HAEMATOLOGY BUSINESS
Slide 23: EMERALD-3 enhances our growing presence in GI cancers
EMERALD-3 enhances our growing presence in GI cancers EMERALD-3 | meaningful advance in Maturing pipeline of innovative regimens across embolisation-eligible liver cancer range of GI cancers Today Next ~18mo >2027 ~390k1 patients | early-stage HCC MATTERHORN KUNLUN ARTEMIDE- Gastric01 GASTRIC/ GEJ/
Slide 24: Continued expansion of Imfinzi – the fastest growing PDx
Continued expansion of Imfinzi – the fastest growing PDx Deliver Imfinzi combinations PACIFIC-9 + oleclumab/monalizumab Move into earlier stage cancers AVANZAR + Datroway + CTx AEGEAN EMERALD-3 DeLLphi-3051 + tarlatamab ADRIATIC EMERALD-1 NILE + CTx +/- Imjudo Establish our foundation PACIFIC-4 EMER
Slide 25: Extending leadership in breast cancer
Extending leadership in breast cancer SERENA-6 | camizestrant only oral next generation TROPION-Breast02 | Datroway first and only therapy SERD with Phase III data in 1L HR+ aBC to significantly improve overall survival vs CTx in TNBC where IO is not an option ASCO | PFS2, ctDNA clearance data linke
Slide 26: Establishing the pipeline for tomorrow
Establishing the pipeline for tomorrow Susan Galbraith EVP, ONCOLOGY HAEMATOLOGY R&D
Slide 27: BLUESTAR data position puxi-sam as potential best-in-class ADC
BLUESTAR data position puxi-sam as potential best-in- class ADC in B7-H4-positive endometrial cancer BLUESTAR Phase I/IIa | puxi-sam 2.4mg/kg in 2L+ B7-H4+ advanced endometrial cancer Leading in Phase III 100 development Best objective response Histology 80 PD Serous SD Endometrioid Best change from
Slide 28: Advancing ADC programme in gynaecological cancers with torvu-sam
Further advancing our ADC programme in gynaecological cancers with torvu-sam in ovarian cancer torvu-sam| leading programme in ovarian cancer Broadening torvu-sam FRα is a strongly validated target for ADCs in ovarian cancer Phase III programme – High FRα is a negative prognostic factor in ovarian 2
Slide 29: Global data support potential of sone-ve in Claudin18.2-positive gastric cancer
Global data support potential of sone-ve in Claudin18.2-positive gastric cancer CLARITY-PanTumor01 Phase II | global trial of Broadening Phase III sone-ve of Claudin18.2+ 2L+ gastric/GEJC programme 2L+ setting | n=67 monotherapy CLARITY-Gastric01 Data H2 2026 1L setting | + CTx +/- IO Includes rilve
Slide 30: Further data builds confidence in IO bispecific portfolio
Further data builds confidence in IO bispecific portfolio rilvegostomig volrustomig GEMINI-HPB Phase II1 DESTINY-Gastric03 Phase Ib/II2,3 eVOLVE-02 Phase II4 rilvegostomig + CTx in advanced BTC rilvegostomig + Enhertu + FP in HER2+ volrustomig in recurrent/metastatic PD- (n=305) advanced gastric/GEJ
Slide 31: Expanding haematology pipeline with AZD3470
Expanding haematology pipeline with AZD3470 AZD3470 | MTAP-selective PRMT5 PRIMAVERA | AZD3470 in relapsed/ inhibitor refractory classic Hodgkin lymphoma First 2nd generation PRMT5i in haematology ORR 63% ORR 53% PR 19% Novel in-house identified MTAP silencing mechanism PR 27% MTA-cooperative mechan
Slide 32: CARES demonstrates benefit of anselamimab in kappa-isotype AL amyloidosis
CARES demonstrates benefit of anselamimab in kappa-isotype AL amyloidosis anselamimab | chimeric CARES | Two Phase III trials of anselamimab in light IgG1κ mAb chain amyloidosis Highly clinically meaningful improvements in kappa isotype In AL amyloidosis, amyloid fibrils Trials did not meet primary
Slide 33: Significant progress at ASCO towards Oncology strategy
Significant progress at ASCO towards Oncology strategy to redefine cancer care Novel ADCs and 1 Replace the backbone of chemotherapy and radiotherapy Radioconjugates Novel IO 2 Next wave of IO agents will segment the IO-sensitive space Cell therapy and 3 Scalable, accessible therapies in both liquid
Slide 34: Opportunity for Q&A
Opportunity for Q&A Pascal Soriot Susan Galbraith CH IEF E XECUTI VE O FFICE R E VP, ONCOLO GY HAE MATOL OGY R& D Dave Fredrickson Gianluca Pirozzi E VP, ONCOLO GY SVP, H EAD OF D EVEL OPMENT , HAE MATOL OGY BUSINE SS RE GUL ATOR Y & SAFET Y 34
Slide 35: Meet AZN Management: ASCO 2026 Appendix
Meet AZN Management: ASCO 2026 APPENDIX
Slide 36: Glossary
Glossary • (a)BTC 1L, 2L, 3L a/mBC ADC (advanced) biliary tract cancer first-, second-, third-line advanced/metastatic breast cancer antibody drug conjugate HER2+/positive HER2m HNSCC HR human epidermal growth factor receptor 2-positive human epidermal growth factor receptor 2-mutant head and neck s
Slide 37: AstraZeneca in non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON PACIFIC Datroway + IO ± platinum TL0
Slide 38: AstraZeneca in breast cancer
APPEN DI X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breast
Slide 39: AstraZeneca in gastric cancer
APPEN DI X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu + pe
Slide 40: AstraZeneca in bladder cancer
APPEN DI X | Oncology tumour maps AstraZeneca in bladder cancer High-risk NMIBC MIBC 1L mUC 96k 68k 46k Neoadjuvant Imfinzi + CTx → adjuvant Imfinzi NIAGARA cis-eligible ~50% Imfinzi + BCG induction and maintenance Imfinzi + CTx ± Imjudo POTOMAC NILE Neoadjuvant Imfinzi + enfortumab vedotin ± Imjudo
Slide 41: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis